Header Logo

Connection

Michelle Callegan to Eye Infections, Bacterial

Back to Details
This is a "connection" page, showing publications Michelle Callegan has written about Eye Infections, Bacterial.
Michelle Callegan
Connection Strength
16.421
Eye Infections, Bacterial
  1. Contribution of Leukocidin ED to the Pathogenesis of Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2025 May 01; 66(5):11.
    View in: PubMed
    Score: 0.862
  2. Novel Anti-Microbial/Anti-Inflammatory Combination Improves Clinical Outcome of Bacillus cereus Endophthalmitis. Invest Ophthalmol Vis Sci. 2025 Jan 02; 66(1):39.
    View in: PubMed
    Score: 0.843
  3. The Role of CCL Chemokines in Experimental Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2024 Jun 03; 65(6):12.
    View in: PubMed
    Score: 0.810
  4. Roles of CCL2 and CCL3 in intraocular inflammation during Bacillus endophthalmitis. Exp Eye Res. 2022 11; 224:109213.
    View in: PubMed
    Score: 0.717
  5. C-X-C Chemokines Influence Intraocular Inflammation During Bacillus Endophthalmitis. Invest Ophthalmol Vis Sci. 2021 11 01; 62(14):14.
    View in: PubMed
    Score: 0.677
  6. Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis. J Vis Exp. 2021 02 06; (168).
    View in: PubMed
    Score: 0.643
  7. Innate Immune Interference Attenuates Inflammation In Bacillus Endophthalmitis. Invest Ophthalmol Vis Sci. 2020 11 02; 61(13):17.
    View in: PubMed
    Score: 0.631
  8. The cereus matter of Bacillus endophthalmitis. Exp Eye Res. 2020 04; 193:107959.
    View in: PubMed
    Score: 0.600
  9. S-layer Impacts the Virulence of Bacillus in Endophthalmitis. Invest Ophthalmol Vis Sci. 2019 09 03; 60(12):3727-3739.
    View in: PubMed
    Score: 0.582
  10. Targets of immunomodulation in bacterial endophthalmitis. Prog Retin Eye Res. 2019 11; 73:100763.
    View in: PubMed
    Score: 0.572
  11. Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections. mSphere. 2019 05 15; 4(3).
    View in: PubMed
    Score: 0.570
  12. TLR4 modulates inflammatory gene targets in the retina during Bacillus cereus endophthalmitis. BMC Ophthalmol. 2018 Apr 16; 18(1):96.
    View in: PubMed
    Score: 0.529
  13. The role of pili in Bacillus cereus intraocular infection. Exp Eye Res. 2017 06; 159:69-76.
    View in: PubMed
    Score: 0.491
  14. CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection. J Leukoc Biol. 2016 11; 100(5):1125-1134.
    View in: PubMed
    Score: 0.466
  15. Bloodstream-To-Eye Infections Are Facilitated by Outer Blood-Retinal Barrier Dysfunction. PLoS One. 2016; 11(5):e0154560.
    View in: PubMed
    Score: 0.464
  16. Modeling intraocular bacterial infections. Prog Retin Eye Res. 2016 09; 54:30-48.
    View in: PubMed
    Score: 0.462
  17. Blood-Retinal Barrier Compromise and Endogenous Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2015 Nov; 56(12):7303-11.
    View in: PubMed
    Score: 0.446
  18. Role of TLR5 and flagella in bacillus intraocular infection. PLoS One. 2014; 9(6):e100543.
    View in: PubMed
    Score: 0.406
  19. TLR4 contributes to the host response to Klebsiella intraocular infection. Curr Eye Res. 2014 Aug; 39(8):790-802.
    View in: PubMed
    Score: 0.398
  20. The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis. Invest Ophthalmol Vis Sci. 2012 Nov 01; 53(12):7426-31.
    View in: PubMed
    Score: 0.363
  21. Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis. PLoS One. 2011; 6(12):e28619.
    View in: PubMed
    Score: 0.341
  22. Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis. Retina. 2011 Sep; 31(8):1518-24.
    View in: PubMed
    Score: 0.334
  23. Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2011 Aug 29; 52(9):6860-6.
    View in: PubMed
    Score: 0.334
  24. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009 Apr; 26(4):447-54.
    View in: PubMed
    Score: 0.284
  25. Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Nov; 49(11):4931-8.
    View in: PubMed
    Score: 0.268
  26. A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci. 2008 Oct; 49(10):4482-9.
    View in: PubMed
    Score: 0.268
  27. Toward improving therapeutic regimens for Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Apr; 49(4):1480-7.
    View in: PubMed
    Score: 0.264
  28. Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res. 2007 Mar; 26(2):189-203.
    View in: PubMed
    Score: 0.243
  29. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res. 2006 Nov; 31(11):955-65.
    View in: PubMed
    Score: 0.239
  30. Role of swarming migration in the pathogenesis of bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4461-7.
    View in: PubMed
    Score: 0.238
  31. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005 Sep; 46(9):3233-8.
    View in: PubMed
    Score: 0.221
  32. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003 Sep-Oct; 20(5):246-52.
    View in: PubMed
    Score: 0.192
  33. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002 Jan; 15(1):111-24.
    View in: PubMed
    Score: 0.171
  34. Corticosteroid and antibiotic therapy for bacillus endophthalmitis. Arch Ophthalmol. 2001 Sep; 119(9):1391-3.
    View in: PubMed
    Score: 0.167
  35. Immune Inhibitor A Metalloproteases Contribute to Virulence in Bacillus Endophthalmitis. Infect Immun. 2021 09 16; 89(10):e0020121.
    View in: PubMed
    Score: 0.165
  36. An Eye on Staphylococcus aureus Toxins: Roles in Ocular Damage and Inflammation. Toxins (Basel). 2019 06 19; 11(6).
    View in: PubMed
    Score: 0.144
  37. Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Curr Eye Res. 1994 Dec; 13(12):875-8.
    View in: PubMed
    Score: 0.105
  38. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet. 1994 Aug; 27(2):129-49.
    View in: PubMed
    Score: 0.102
  39. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci. 1994 Mar; 35(3):1033-7.
    View in: PubMed
    Score: 0.099
  40. The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva. J Ocul Pharmacol Ther. 2013 Jun; 29(5):450-5.
    View in: PubMed
    Score: 0.093
  41. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res. 1992 Nov; 11(11):1111-9.
    View in: PubMed
    Score: 0.091
  42. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992 Oct; 33(11):3017-23.
    View in: PubMed
    Score: 0.090
  43. Checks and balances: the ocular response to infection. Virulence. 2010 Jul-Aug; 1(4):222.
    View in: PubMed
    Score: 0.077
  44. Role of bacterial and host factors in infectious endophthalmitis. Chem Immunol Allergy. 2007; 92:266-275.
    View in: PubMed
    Score: 0.061
  45. Virulence factor profiles and antimicrobial susceptibilities of ocular bacillus isolates. Curr Eye Res. 2006 Sep; 31(9):693-702.
    View in: PubMed
    Score: 0.059
  46. Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci. 2002 May; 43(5):1414-21.
    View in: PubMed
    Score: 0.044
  47. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens. Cornea. 2000 Jul; 19(4):539-45.
    View in: PubMed
    Score: 0.039
  48. Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci. 1996 Mar; 37(4):534-43.
    View in: PubMed
    Score: 0.029
  49. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol. 1996; 40(2):212-9.
    View in: PubMed
    Score: 0.028
  50. Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea. Curr Eye Res. 1995 Apr; 14(4):281-4.
    View in: PubMed
    Score: 0.027
  51. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995 Mar; 14(3):229-34.
    View in: PubMed
    Score: 0.027
  52. Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res. 1993 May; 12(5):461-7.
    View in: PubMed
    Score: 0.023
  53. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1993 May; 12(5):469-73.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.